Enovis (ENOV)

• Market cap: $1.9B
• 1 day: 3.55%
• 5 days: 1.49%
• 1 month: 12.59%
• 3 months: 8.51%
• 6 months: -14.71%
• Year to date: -24.9%
• 1 year: -23.76%
• 5 years: -42.21%
• 10 years: -43.63%
• Sector: Healthcare
• Industry: Medical Devices

About: Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Employees: 7,367

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

201% more call options, than puts

Call options by funds: $51.7M | Put options by funds: $17.2M

51% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 77

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

3.23% more ownership

Funds ownership: 115.06% [Q1] → 118.29% (+3.23%) [Q2]

7% less first-time investments, than exits

New positions opened: 56 | Existing positions closed: 60

3% less funds holding

Funds holding: 291 [Q1] → 282 (-9) [Q2]

15% less capital invested

Capital invested by funds: $2.5B [Q1] → $2.12B (-$386M) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $41
• Avg. target: $50
• High target: $58

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin	$58	Buy Maintained	8 Aug 2025
UBS Danielle Antalffy	$57	Buy Maintained	8 Aug 2025
Wells Fargo Vik Chopra	$41	Overweight Maintained	8 Aug 2025
Needham Mike Matson	$49	Buy Maintained	7 Aug 2025
Evercore ISI Group Vijay Kumar	$46	Outperform Maintained	8 Jul 2025